About Index Trending news
Analyze
Top 50 Pricing
Intellia Therapeutics

Intellia Therapeutics

Work at Intellia Therapeutics? Add yourself to this profile

Intellia Therapeutics

Treating genetic disease at the cutting edge: Intellia Therapeutics is a CRISPR/Cas9 focused biotechnology company.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
IPO
$108,000,000
Venture capital (Series B)
$70,000,000
Employees

Team size

10+
Locations
HQ
Xconomy

CRISPR Drug Maker Intellia Therapeutics Sells $108M In IPO Shares

Xconomy

With CRISPR in Humans On The Horizon, Will the Public Back Intellia?

Xconomy

CRISPR Developer Intellia Deals With Regeneron, Jumps Into IPO Queue